-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biliary tract cancer (BTC) is a heterogeneous group of malignancies including intrahepatic cholangiocarcinoma (CCA), extrahepatic cholangiocarcinoma, and gallbladder carcinoma
.
There are few effective treatment options for biliary tract cancer
The current standard first-line palliative treatment for biliary tract cancer is a combination of gemcitabine and cisplatin
This is a single-arm Phase II clinical trial recruiting patients with unresectable, previously treated ECOG 0/1 advanced cholangiocarcinoma, and certain liver, kidney and bone marrow function requirements
.
Ramucirumab dose: 8 mg/kg every 2 weeks
Secondary endpoints included overall response rate (ORR), disease control rate (DCR), overall survival (OS) and toxicity
Progression-Free Survival and Overall Survival
Progression-Free Survival and Overall Survival
The median treatment duration was 10.
1 weeks
.
Median PFS was 3.
Median PFS was 3.
In conclusion, the findings of this study suggest that ramucirumab was well tolerated in patients with advanced cholangiocarcinoma with a PFS similar to other chemotherapy regimens historically used for chemotherapy-refractory cholangiocarcinoma
.
.
Original source:
Original source:Sunyoung Lee; Rachna T.
leave a message here